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The COVID-19 pandemic has led to widespread disruption in the delivery of health care with a 
significant impact on patients, healthcare professionals and health systems.1 It is unknown how 
cardiovascular clinical research has been disrupted. To understand how COVID-19 has affected 
site-based heart failure (HF) clinical research operations, we queried sites participating in the 
CONNECT-HF clinical trial. 
 
Methods 
The data that support the findings of this study are available from the corresponding author upon 
reasonable request. Leveraging the infrastructure of the CONNECT-HF trial, a 12-question 
electronic survey designed to assess changes in HF-related clinical research activities was 
developed by expert consensus and sent to all CONNECT-HF site clinical research coordinators 
(CRCs). CONNECT-HF is a prospective, cluster-randomized trial of 151 HF programs in 36 
states across the US, and designed to assess an in-hospital and post-discharge quality 
improvement intervention, compared to usual care, on HF outcomes and quality of care.2 Survey 
results were compiled and analyzed using descriptive statistics and content analysis was 
performed for free text. This study was approved by the Duke University Institutional Review 
Board.  
 
Results 
Between 5/11/2020 – 5/18/2020 surveys were sent to 131 currently active sites. 87 CRCs (66%) 
responded from 25 academic health systems (29%), 14 large tertiary hospitals (16%), 44 
community hospitals (51%), and 4 public health centers (4.6%). Figure 1 shows the proportions 
of ongoing HF research at CONNECT-HF sites. Only 11.5% of sites with active research 
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activities designated CONNECT-HF as essential. Half of responders reported that 30% or less of 
their responsibilities were converted to remote work.   
 As of May 2020, 32% of sites had resumed clinical research activities, 27% planned to 
loosen restrictions in the next 2-3 months, and 41% had no plans to resume.  There was 
considerable variation in where sites obtained guidance when determining how to resume clinical 
research activities: 5.2% followed federal guidance, 28% used state guidelines, and 7.2% used 
city/county guidance. Over half of reporting sites used a source not listed or were not aware of 
specific guidance.  
 A wide spectrum of comfort-level with respect to clinical research staff returning to the 
hospital was reported. 42% of responders reported at least some degree of fear associated with 
returning, 32% expressed little to no fear, and 26% reported feeling neutral. 59% reported not 
having clinical research staff furloughed and 96% of sites had not experienced permanent staff 
termination.  
 
Discussion 
The results of this survey demonstrate the extent to which COVID-19 has obstructed various 
aspects of HF site-based research. Over half of CONNECT-HF sites have had major disruptions 
or complete cessation of all HF clinical research activity with substantial research coordinator 
work unable to be completed virtually. Furthermore, plans and guidance used to reopen HF 
research activities were variable.   
 To our knowledge, this survey represents the first attempt to quantify the impact of 
COVID-19 on site-based clinical research. This survey demonstrates how COVID-19 has 
identified inefficiencies in the clinical trial ecosystem.   During the COVID-19 pandemic, 
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regulatory agencies have advocated for operating clinical research programs with flexibility; 
ensuring the safety of trial participants, maintaining compliance with good clinical practice, and 
minimizing risk to trial integrity.3,4 Unfortunately, these recommendations do not provide 
tangible ways to ensure continuation of research activity. By reducing in-person visits to keep 
participants and staff safe, it is unclear how slowed enrollment, delayed follow-up visits, and not 
having ways for reliable safety assessment will affect future outcomes actively enrolling clinical 
trials. Because CONNECT-HF is a cluster-randomized trial that promotes guideline-based care 
and thus is low risk to patients, it is suited to converting to virtual enrollment and follow-up. 
Trials of novel therapeutics or for new therapeutic indications may not have this same flexibility 
given higher stakes in potential direct patient effects.  
Regulatory and professional society recommendations also lack guidance on when or 
how to resume in-person clinical research operations.3,4 This is reflected in variable responses 
about timing of reopening and guidance for reopening. A substantial number of survey 
responders expressed significant fear about returning to work. We did not assess whether fear of 
COVID-19 exposure would make research staff less likely to approach patients for research 
participation, though this would provide further justification for creation of robust digital 
platforms to conduct important research related activity. We also did not assess how patients will 
perceive enrollment in clinical trials as COVID-19 restrictions are lifted. Finally, this survey was 
created to ascertain changes to HF research activities in general; however, these findings may not 
be generalizable to broader cardiovascular research in general.  
Conclusions 
The COVID-19 pandemic has led to widespread disruption in the daily delivery of health care 
with a significant impact on HF clinical trials. This study demonstrated that COVID-19 has 
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significantly interrupted HF site-based research activities across the US, staff has limited access 
to avenues for virtual work, and plans to resume activities are varied. Conversion to virtual 
platforms, when feasible, would potentially help alleviate many of these issues.  
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Figure Legend 
 
Figure.  Bar graphs representing answers to survey questions. HF=Heart failure. 
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